drugset
drugset / Trial / NCT00788541

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541 ↗

Phase 2 Terminated 197 enrolled Alcon Research
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2008-12
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 3 mg Other
Subject Anecortave Acetate Small molecule 48 mg Other

Indications

ocular hypertension open-angle glaucoma